Laura Esserman

MD MBA

Director, Carol Franc Buck Breast Care Center

About me

Dr. Laura Esserman, a nationally known breast surgeon, directs the UCSF Carol Franc Buck Breast Care Center at the Mount Zion campus. Her work is devoted to developing new, more effective ways to care for and empower breast cancer patients during treatment. She tailors treatments for individual patients using biology, personal preference and constant feedback regarding outcomes of care.

Esserman earned her undergraduate degree at Harvard University and completed her medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford and later earned a master's degree from the Stanford Graduate School of Business. She joined UCSF Medical Center in 1993.

  • Education

    Stanford University, 1983

  • Residencies

    Stanford University, General Surgery, 1991

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title

    Professor

  • Languages

    Spanish

Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

My reviews

4.8

Overall Experience
71 Reviews
I wish every woman with breast cancer could see Dr. Esserman
Explained things in a way that was easy to understand
71 Reviews
Did the doctor pay attention to your concerns
71 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
69 Reviews
Knew the important information about your medical history
71 Reviews
The provider showed respect for what you had to say
71 Reviews
The provider spent enough time with me
71 Reviews
Decorative Caduceus

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting

Decorative Caduceus

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Proportion of cancers diagnosed at Stage IIB or higher

Recruiting

Decorative Caduceus

Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)

To determine the maximum tolerated dose (MTD), and recommended dose for subsequent expansion cohort, of intralesionally administered pembrolizumab in patients with ductal carcinoma in situ (DCIS) of the breast.

Recruiting

Share